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Purpose: To assess the importance of inflammation in chronic obstructive pulmonary disease 
(COPD) by measuring airway and systemic inflammatory biomarkers in Japanese patients with 
the disease and relevant control groups.
Patients and methods: This was the first study of its type in Japanese COPD patients. It 
was a non-treatment study in which 100 participants were enrolled into one of three groups: 
nonsmoking controls, current or ex-smoking controls, and COPD patients. All participants 
underwent standard lung function assessments and provided sputum and blood samples from 
which the numbers of inflammatory cells and concentrations of biomarkers were measured, 
using standard procedures.
Results: The overall trends observed in levels of inflammatory cells and biomarkers in sputum 
and blood in COPD were consistent with previous reports in Western studies. Increasing levels 
of neutrophils, interleukin 8 (IL-8), surfactant protein D (SP-D), and Krebs von den Lungen 6 
(KL-6) in sputum and clara cell 16 (CC-16), high-sensitivity C-reactive protein (hs-CRP), and 
KL-6 in serum and plasma fibrinogen were seen in the Japanese COPD patients compared 
with the non-COPD control participants. In sputum, significant correlations were seen between 
total cell count and matrix metalloproteinase 9 (MMP-9; P0.001), neutrophils and MMP-9 
(P0.001), macrophages and KL-6 (P0.01), total cell count and IL-8 (P0.05), neutrophils 
and IL-8 (P0.05), and macrophages and MMP-9 (P0.05). Significant correlations were 
also observed between some inflammatory cells in sputum and biomarkers in serum, with the 
most significant between serum CC-16 and both total cell count (P0.005) and neutrophils 
(P0.005) in sputum.
Conclusion: These results provide evidence for the first time that COPD in Japanese patients 
is a multicomponent disease, involving both airway and systemic inflammation, in addition 
to airway obstruction. Therefore, intervention with anti-inflammatory therapy may provide 
additional benefit in disease management of COPD in Japan.
Keywords: chronic obstructive pulmonary disease, inflammatory cells, biomarkers, sputum, 
serum
Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death 
globally, with a projected increase in burden resulting from continued exposure to 
COPD risk factors and an aging population.1 From 1995 to 2005, a survey by the 
Japanese Ministry of Health and Welfare reported a prevalence of COPD of 0.2%–0.4% 
in Japan,2 and there is a belief that COPD in Japan is different than in the West.3 How-
ever, recent data indicate the prevalence of airflow limitation to be 10.9%, suggesting 
under-recognition of COPD in Japan,3 and the phenotypic distribution is similar to 
that previously described in Western studies.4 COPD is an inflammatory lung disease 
caused by long-term inhalation exposure to noxious substances, most commonly 
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tobacco smoke.1,4 It is characterized by incompletely revers-
ible airflow limitation, resulting from varying degrees of 
small airways disease and emphysema, and it is progressive.1 
Inflammation of the respiratory tract may be involved both 
in the development of COPD and the progression of airflow 
limitation.1,5 Indeed, Japanese and world guidelines define 
COPD as an inflammatory disease of the lung.1,2 However, 
increasing evidence suggests COPD symptoms are also 
associated with abnormal systemic inflammatory responses, 
making COPD a multicomponent disease.6–9 Increased air-
way and systemic inflammation have been associated with 
COPD exacerbations and physiological changes such as 
hyperinflation.10,11
To this end, inflammatory biomarkers have become a 
useful means of characterizing the extent of both airway 
and systemic inflammation associated with COPD and 
for measuring the anti-inflammatory effects of treatment, 
especially given the high variability observed in the rate 
of decline of forced expiratory volume in 1 second (FEV
1
) 
as an endpoint.12–14 However, serum and sputum inflamma-
tory biomarkers in Japanese patients with COPD have not 
been studied extensively. In this study, we have selected 
a panel of biomarkers based on previous studies, such as 
ECLIPSE (Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate Endpoints), in COPD. For example, in 
exacerbations of COPD, it has been reported that inflamma-
tory cells such as neutrophils and eosinophils are increased 
in sputum.11 Interleukin 8 (IL-8) in sputum is associated 
with increased chemotaxis of activated neutrophils and 
eosinophils.15 Matrix metalloproteinase 9 (MMP-9) has also 
been related to the pathogenesis of COPD,15 and clara cell 
secretory protein 16 (CC-16) in blood and pulmonary sur-
factant protein (SP) A and Krebs von den Lungen 6 (KL-6) 
have been postulated to represent a biomarker, especially 
for fibrosis of the lung.
The novelty and importance of the present study is that 
it is the first to assess both airway and systemic inflamma-
tion (using induced sputum and serum samples) in Japanese 
COPD patients compared with smoking and nonsmoking 
control participants. It proved impossible in this population 
to include a group of COPD patients without a smoking 
history.
Materials and methods
subjects
A total of 100 Japanese men and women, aged 40 years 
or older, were enrolled who were either nonsmokers (non-
smoking control participants) who had not smoked for the 
past 6 months with a pack history of 1 pack a year or less 
and no diagnosis of COPD, current or ex-smokers (smok-
ing control participants) with a pack history of 10 or more 
years and no diagnosis of COPD, or current or ex-smokers 
with a diagnosis of COPD (COPD patients) with a pack 
history of 10 or more years and cough or sputum 2 or fewer 
weeks before entry to the study. The diagnosis of COPD 
was defined according to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria, with a prebron-
chodilator FEV
1
/forced vital capacity (FVC) lower than 0.7.1 
Participants assigned as nonsmoking control patients 
and smoking control patients had no airway obstruction 
(prebronchodilator FEV
1
/FVC 0.7). Participants were 
excluded if they had a diagnosis of bronchial asthma or any 
respiratory disorder other than COPD; had undergone lung 
volume reduction or lung transplant; had a chest X-ray (or 
computed tomography [CT] scan) indicating major disease 
other than COPD that may interfere with study assessments; 
had a respiratory infection within 4 weeks before screening; 
used inhaled corticosteroids and systemic corticosteroids or 
low-dose xanthines (use at a regular dose was allowable) 
2 or fewer weeks before screening; had a bacterial infec-
tion, viral infection (including viral hepatitis), or systemic 
inflammation at enrolment; or had a known α1-antitrypsin 
deficiency. All participants gave, in writing, their informed 
consent and permission to use their samples. 
study design
This was a non-treatment study conducted between 
November 2012 (first subject, first visit) and November 2013 
(statistical analysis completed) at the Hiroshima University 
Hospital, Japan. The study was conducted in accordance 
with the ethical principles of the Declaration of Helsinki 
and was approved by the Ethics Committee of Hiroshima 
University Hospital.
Participants attended the study center once for an initial 
medical examination and study-related assessments. If par-
ticipants did not reach their cough and sputum status, they 
could return to the site for a retest 2 or more weeks after the 
initial visit. Undesirable medical events, including serious 
adverse events, were monitored during and between both 
study visits.
assessments
At the study visit, participants underwent standard lung 
function assessments (FEV
1
, FVC, % predicted FEV
1
 and 
FEV
1
/FVC)16 and had a chest X-ray if one had not been 
performed within 6 months of the study visit. Impulse 
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Oscillation System (IOS) parameters were measured, as 
previously described.17,18 Values at an airway resistance of 
5 Hz (R5) and 20 Hz (R20) and airway reactance of 5 Hz 
(X5) were used for analysis. Airway resistance and reactance 
were assessed as measurements averaged over several tidal 
breaths (whole-breath analysis). Sputum specimens were 
obtained according to guidelines of the European Respiratory 
Society’s Task Force, as previously described.19,20 In brief, 
a sputum induction procedure was conducted using 3%–5% 
hypertonic saline given at 5 minute intervals for a maximum 
of 15 minutes via an ultrasonic nebulizer NE-U12 (Omron 
Co, Kyoto, Japan). Inflammatory cell counts (neutrophil, 
eosinophil, lymphocyte, macrophage, and total inflammatory 
cell) from induced sputum were measured using fixed cell 
samples by Diff-Quick staining in the Hiroshima University 
laboratory. Inflammatory biomarkers were measured using 
standard immunochemical assays by SRL Medisearch Inc 
(Sagamihara, Japan) collected from sputum supernatant; 
IL-8 [enzyme-linked immunosorbent assay {ELISA}], KL-6 
[electro-chemiluminescence immunoassay], SP-A [enzyme 
immunoassay {EIA}], SP-D [EIA], hs-CRP [latex-enhanced 
nephelometry], or MMP-9 [EIA], serum; IL-8 [ELISA], 
KL-6 [enzyme-linked immune-culture assay], CC-16 
[ELISA], SP-A [EIA], SP-D [EIA], hs-CRP [latex-enhanced 
nephelometry], and plasma; fibrinogen, measured using the 
thrombin clotting time test with a detection limit of 20 mg/
dL. CC-16 was not measured in sputum, as previous studies14 
showed it was not a descriptive factor in COPD.
statistical methods
The target number of participants was 100, of whom 50 were 
COPD patients, 30 were smoking control participants, and 
20 were nonsmoking control participants. Inflammatory cell 
counts, the percentage of inflammatory cells, and concentra-
tion of inflammatory biomarkers were analyzed using the 
Dunnett’s multiple comparison nonparametric test to compare 
the COPD, non-COPD smoker, and non-COPD nonsmoker 
groups. Stratified analyses were then conducted according 
to subject baseline factors. The per protocol (PP) set was the 
primary data set for analysis. Correlation between variables 
was assessed by Spearman’s rank correlation coefficient.
Results
subject population
Demographic data are summarized in Table 1. The three 
subject groups were generally similar with respect to age, 
height, and weight; the smoking control participant group 
and COPD group were similar with respect to the number 
of pack-years. However, there was a predictable statisti-
cally significant difference between COPD patients versus 
Table 1 summary of demographics and spirometry measurements
Demographics and measurements Nonsmoker control Smoker control COPD
Participants, n 20 30 47
Demographics
age, years 59.0±10.2 62.7±12.1 70.8±8.1
sex, males/females 10/10 28/2 45/2
height, cm 160.6±7.3 165.8±7.5 163.5±6.7
Weight, kg 62.3±11.0 66.6±10.0 62.3±9.6
smoking history
Current/former/never 0/3/17 9/21/0 13/34/0
number of pack-years 0.34±0.3 57.3±105.9 62.3±44.7
spirometry
FVC, l 3.03±0.69 3.72±0.94 3.18±0.76
FeV1, l 2.47±0.55* 2.91±0.80† 1.92±0.56
FeV1, % predicted 95.0±11.7* 96.5±16.9† 71.3±17.4
FeV1/FVC 81.8±6.8† 78.1±5.6† 60.2±9.1
Whole-breath Impulse Oscillation system results
r5, kPa/l/second 0.283±0.113‡ 0.242±0.121¶ 0.341±0.149
r20, kPa/l/second 0.248±0.089§ 0.219±0.076 0.262±0.078
X5, kPa/l/second -0.112±0.03§ -0.106±0.09‡ -0.170±0.12
Notes: Demographic data are shown as number of subjects or raw means ± standard deviation, as appropriate. spirometry data are shown as number of subjects or 
adjusted means ± standard error, as appropriate. The Dunnett’s test was conducted by comparing with each adjusted mean values. *P0.0005 (difference between COPD 
and nonsmoker control or smoker control groups, by the Dunnett’s test). †P0.0001 (difference between COPD and nonsmoker control or smoker control groups, by 
the Dunnett’s test). ‡P0.01 (difference between COPD and nonsmoker control or smoker control groups, by the Dunnett’s test). ¶P0.005 (difference between COPD 
and nonsmoker control or smoker control groups, by the Dunnett’s test). §P0.05 (difference between COPD and nonsmoker control or smoker control groups, by the 
Dunnett’s test).
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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both smoking control participants and nonsmoking control 
participants with respect to FEV
1
, FEV
1
 % predicted, and 
FEV
1
/FVC. There was also a statistically significant dif-
ference between COPD patients and both smoking control 
participants and nonsmoking control participants with 
respect to all the IOS parameters, with the exception of 
R20, a marker of mean airway resistance of central airways, 
for COPD patients versus smoking control participants. 
The PP population comprised 97 of 100 participants, as 
three participants from the COPD patient group were excluded 
from PP analysis because of concomitant illnesses of fibrosis 
of the lung, asthma, and fibrosis of the lung and kidney cancer, 
respectively. One participant experienced a serious adverse 
event (bronchial asthma attack) during the sputum induction 
procedure and was not enrolled in the study.
Inflammatory cells in sputum
Sputum inflammatory cell data are summarized in Table 2. 
Although no statistically significant differences were 
observed in total cell counts between COPD patients 
and non-COPD control participants, there was a trend 
toward an increase in COPD. The mean sputum total cell 
count ± standard deviation in the COPD group, smoking 
control participants, and nonsmoking control participants 
were 66.5×105±80.8 cells/mL, 45.8×105±40.4 cells/mL and 
39.5×105±30.4 cells/mL, respectively. 
Similarly, no statistically significant differences were 
observed between the COPD patients and non-COPD control 
participants in relation to induced sputum neutrophils and 
macrophages. However, the mean percentage ± standard 
deviation of neutrophils in the COPD group, smoking 
control participants, and nonsmoking control participants 
were 76.3%±15.7%, 69.5%±20.3%, and 67.4%±24.3%, 
respectively, again indicating a trend toward an increase in 
COPD. In contrast, the absolute numbers of macrophages 
were 8.7×105, 9.5×105, and 12.3×105 cells/mL in the COPD 
patients, smoking control participants, and nonsmok-
ing control participants, and the mean percentages were 
16.6%±13.3%, 23.1%±18.0%, and 25.4%±23.7%, respec-
tively, suggesting a marked decrease in COPD patients.
levels of biomarkers in sputum and blood
Biomarker data in sputum and blood are summarized in 
Table 2. 
Median sputum IL-8 levels were significantly higher in 
COPD patients (551.0 pg/mL) than in the smoking control 
Table 2 Summary of inflammatory cells and biomarkers in sputum and blood
Inflammatory biomarkers Nonsmoker control Smoker control Chronic obstructive 
pulmonary disease
Participants, n 20 30 47
Inflammatory cells (sputum)
Total cell count, ×105 cells/ml 39.5±30.4 45.8±40.4 66.5±80.8
neutrophil count, ×105 cells/ml 24.6±21.5 32.7±32.1 53.6±73.6
Macrophage count, ×105 cells/ml 12.3±21.6 9.5±10.0 8.7±9.1
sputum neutrophils, % 67.4±24.3 69.5±20.3 76.3±15.7
sputum macrophages, % 25.4±23.7 23.1±18.0 16.6±13.3
Biomarkers (sputum)
Il-8, pg/ml 336.0 263.0* 551.0
MMP-9, ng/ml 80.0 90.0 130.0
sP-a, ng/ml 95.16 140.0 158.0
sP-D, ng/ml 21.1 24.1 36.7
Kl-6, U/ml 42.8 44.5 71.5
Biomarkers (serum)
Il-8, pg/ml 5.5 5.4 6.0
hs-CrP, ng/dl 327.0 500.0 594.0
CC-16, ng/ml 5.6 6.6 8.5
sP-a, ng/ml 27.0 38.4 39.5
sP-D, ng/ml 45.5 65.2 59.6
Kl-6, U/ml 209.5 248.5 285.5
Biomarkers (plasma)
Fibrinogen, mg/dl 289.0 303.5 300.0
Notes: Sputum inflammatory cell and serum biomarker data are shown as mean ± standard deviation; sputum biomarker data are shown as median value. The nonparametric 
Dunnett’s test was conducted by comparing with each raw median value. *P0.05 (difference between patients with COPD and smoker control patients, by the nonparametric 
Dunnett’s test).
Abbreviations: Il-8, interleukin 8; MMP-9, matrix metalloproteinase 9; sP-a, surfactant protein a; sP-D, surfactant protein D; Kl-6, Krebs von den lungen 6; hs-CrP, 
high-sensitivity C-reactive protein; CC-16, clara cell 16.
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participants (263.0 pg/mL) (P0.05). Although overall, the 
levels of MMP-9, SP-A, SP-D, and KL-6 in sputum were not 
significantly different between COPD patients and the control 
groups, levels of SP-D and KL-6 tended to be higher in the COPD 
patients compared with both non-COPD control groups. 
Mean levels of serum CC-16, hs-CRP, and KL-6 and 
plasma fibrinogen were also higher in COPD patients 
compared with the non-COPD control participants, with 
the lowest values generally seen in the nonsmoking group. 
However, none of the differences seen between the COPD 
patients and control groups were significantly different for 
any of the serum biomarkers.
Correlation between sputum 
inflammatory cells and biomarkers in 
sputum and serum in COPD patients
A summary of correlations in the COPD patients is given in 
Table 3 and Table 4. 
Significant correlations were observed between some inflam-
matory cells in sputum and biomarkers in sputum (Table 3) in 
the COPD patients, with the most significant correlations seen 
between total cell count and MMP-9 (P0.001), neutrophils 
and MMP-9 (P0.001), and macrophages and KL-6 (P0.01). 
Other significant correlations were observed between total cell 
count and IL-8 (P0.05), neutrophils and IL-8 (P0.05), and 
macrophages and MMP-9 (P0.05) (Table 3).
Although not showing a clear association between lung 
and systemic biomarkers of inflammation, which has been 
reported previously, significant correlations were observed 
between some inflammatory cells in sputum and biomarkers 
in serum (Table 4), with the most significant correlations 
observed between serum CC-16 and both sputum total cell 
count (P0.005) and neutrophils (P0.005).
Discussion
COPD is a complex disease involving many different 
types of inflammatory and structural cells, with increasing 
evidence that both pulmonary and systemic inflammatory 
processes are involved.4,21 To add to the complexity, COPD 
is also a heterogeneous disease with interpatient variability.22 
Despite this complexity and heterogeneity, the overall trends 
and correlations observed in this study in levels of sputum 
inflammatory cells and sputum and serum biomarkers sup-
port the presence of pulmonary and systemic inflammation 
in Japanese COPD patients.
In induced sputum, the higher total cell count and neu-
trophil levels tended to be observed in the COPD patients 
compared with the non-COPD control participants; this 
agrees with previous data4 and provides evidence of pul-
monary inflammatory responses occurring in the airways of 
Japanese COPD patients. However, there was a statistically 
significant difference between COPD patients and both smok-
ing control participants and nonsmoking control participants 
with respect to FEV
1
, FEV
1
 % predicted, and FEV
1
/FVC, 
suggesting spirometry is essential in the diagnosis and assess-
ment of severity of COPD. Indeed, studies have shown that 
sputum neutrophils have been directly correlated to the rate 
of annual decline in FEV
1
.23 Furthermore, IOS parameters 
also differ between COPD patients and both smoking control 
participants and nonsmoking control participants. We note 
that IOS is a novel and noninvasive method of evaluating 
respiratory resistance and reactance. 
Macrophages play a pivotal role in COPD pathophysi-
ology. They are activated by cigarette smoke extract to 
release inflammatory mediators, thus providing a cellular 
mechanism by which smoking is linked with inflammation.4 
Marked increases in the number of macrophages in patients 
with COPD have been reported.4,24 However, in our study, 
macrophage levels in induced sputum tended to decrease in 
COPD patients compared with the non-COPD control par-
ticipants, perhaps indicating that macrophages were being 
consumed by the inflammatory process. This concurs with 
several previous reports, where there was a decrease in the 
number of macrophages in COPD.25,26
The significantly higher levels of sputum IL-8 in COPD 
patients compared with in the smoking control group and its 
correlation with the numbers of neutrophils suggest IL-8 may 
be secreted into sputum and then acts as a chemoattractant 
Table 3 Summary of correlation between sputum inflammatory cell counts and sputum biomarkers in patients with COPD
COPD (N=47) Sputum
IL-8, pg/mL MMP-9, ng/mL SP-A, ng/mL SP-D, ng/mL KL-6, U/mL
sputum
number of total cells, ×105 cells/ml 0.3493* 0.5337† 0.1655 0.1077 0.2329
number of neutrophils, ×105 cells/ml 0.3156* 0.5073† 0.1466 0.0967 0.1908
number of macrophages, ×105 cells/ml 0.2758 0.3038* 0.1977 0.2576 0.4058‡
Notes: *P0.05, ‡P0.01, †P0.001 (correlation between variables, by Spearman’s rank correlation coefficient).
Abbreviations: COPD, chronic obstructive pulmonary disease; Il-8, interleukin 8; MMP-9, matrix metalloproteinase 9; sP-a, surfactant protein a; sP-D, surfactant protein D; 
Kl-6, Krebs von den lungen 6.
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for neutrophils migrating into the airway. Neutrophils are 
also a major source of IL-8.4,27 Similarly, there is a strong 
correlation between MMP-9 and the number of neutrophils 
and neutrophils are known to secrete MMP-9.
Higher levels of sputum SP-D, a lung type II pneumocyte-
derived protein, were also observed in COPD patients 
compared with non-COPD control participants, which is in 
agreement with previous data in Japanese subjects.19 SP-D 
has been implicated in the regulation of inflammation and 
pulmonary host defense and was shown to be elevated in 
COPD patients compared with non-COPD control par-
ticipants with prolonged cough; in addition, SP-D levels are 
positively correlated with smoking status.19
 Serum CC-16 levels generally increase after acute 
exposure to smoke; however, there are conflicting data with 
regard to serum levels of CC-16 in COPD.13 For example, in 
the ECLIPSE cohort, serum CC16 levels were decreased in 
COPD relative to non-COPD control participants, and demo-
graphic variability across the study groups was implicated as a 
potential contributing factor.13 Serum CRP is also considered 
one of the signature biomarkers of systemic inflammation.6,28 
Although levels are variable, serum hs-CRP tends to be higher 
in COPD patients compared with in healthy smokers or non-
smokers.29 However, as with CC-16, results can be conflicting 
and may be a result of variable patient selection and differ-
ences in the classification of COPD across studies.6 
As for sputum, serum KL-6 levels also tended to be higher 
in the COPD patient group than in the non-COPD control 
participants. Circulating levels of KL-6 are considered to 
be a sensitive marker for fibrotic lung diseases and are used 
in clinical practice in Japan, alongside SP-A and SP-D, for 
the identification of idiopathic pulmonary fibrosis and other 
types of interstitial lung diseases.19,30 The increase in KL-6 
in COPD in this study is of interest.
Although this study provides evidence that there is both 
pulmonary and systemic inflammation in Japanese COPD 
patients, our results were unable to provide robust evidence 
of any significant relationships between the pulmonary and 
systemic components, which agrees with other data.6,15,31,32 The 
main strength of our study was that the COPD patients enrolled 
represented a typical Japanese patient population. Our study 
also had limitations, including the small sample size, which 
restricted the statistical power of the findings. In addition, not 
all participants had a CT scan during enrolment. In fact, we 
were able to obtain the CT scan results of only 10/50 COPD 
patients, and therefore some of the COPD patients included in 
the analysis may have had undetected lung fibrosis that may 
have affected biomarker concentrations. Furthermore, the 
validation and definition of the specificity of these proteins in 
various phenotypes of COPD (bronchitis vs emphysema pre-
dominance) will require further study. Variability in biomarker 
levels, as seen in our study, especially in induced sputum, and 
even in stable COPD patients, is well-documented and can 
confound results.15,33 Finally, measuring biomarker levels in 
induced sputum rather than biopsy samples means the results 
are more likely to reflect inflammation in the central, rather 
than lower and peripheral, airways.19
Conclusion
This is the first study to investigate both airway and systemic 
inflammation in COPD in Japanese subjects compared with 
the respective smoking and nonsmoking control groups. 
Our results provide further evidence that COPD in Japanese 
patients is a multicomponent disease, involving both 
airway and systemic inflammation, in addition to airway 
obstruction.
These results suggest that intervention with anti- 
inflammatory therapy may provide additional benefit for 
disease management of COPD in Japan. This now needs to 
be considered in a controlled setting.
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